Ben-Hur Herzl, Kossoy George, Mehrdad Herbert, Elhayany Asher, Zusman Itshak
Laboratory of Experimental Medicine, Park Rabin, Rehovot, Israel.
Oncol Rep. 2004 Dec;12(6):1329-33.
We showed previously that soluble tumor-associated antigens (sTAA) isolated from breast cancer patients could suppress chemically-induced tumorigenesis in rats in comparison to the effect of commercial human albumin (CHA). Herein we analyze the possible mechanism of those findings. The following groups of mammary tumor-bearing rats were used in the studies: i) control rats treated with saline; ii) rats treated with CHA; and iii) rats treated with human sTAA. Different zones of the spleen, regional lymph nodes and tumors and their cellular content (B and T cells) were analyzed using the methods of morphometry and immunohistochemistry. Treatment of tumor-bearing rats with CHA resulted in a significant decrease in the size of the germinal center of the follicles. The number of B lymphocytes in the mantle layer of the follicles, the marginal zone and red pulp decreased significantly. The number of CD8+ T cells also decreased in the marginal zone and red pulp, whereas the number of CD4+ T cells increased in the periarterial lymph sheath (PALS) and the red pulp. Reaction of the spleen to vaccination with sTAA manifested in a significant increase in the size of most areas of the white pulp and in the number of B lymphocytes. In lymph nodes from control rats or those treated with CHA, CD8+ lymphocytes mainly accumulated in the paracortical zone. In rats treated with sTAA, CD8+ lymphocytes accumulated also in the medulla. The number of CD4+ T cells in these rats sharply increased and accumulated mainly in the medulla around the vessels. The total number of lymphocytes was changed differently in different areas of tumors (peripheral vs. at depth). The number of CD8+ cells significantly increased at depth of tumors, and also the ratio in the number of these cells at depth of tumors compared to a periphery increased. No difference was found in response of lymph cells to different types of treatment. All findings indicated a strict antitumor effect of vaccination with the sTAA, which prevents the development of insufficiency of the immune system when an intensive immune reaction takes place.
我们之前的研究表明,与市售人白蛋白(CHA)相比,从乳腺癌患者中分离出的可溶性肿瘤相关抗原(sTAA)可抑制大鼠化学诱导的肿瘤发生。在此我们分析这些研究结果的可能机制。本研究使用了以下几组荷乳腺肿瘤大鼠:i)用生理盐水处理的对照大鼠;ii)用CHA处理的大鼠;iii)用人sTAA处理的大鼠。使用形态计量学和免疫组织化学方法分析脾脏、区域淋巴结和肿瘤的不同区域及其细胞成分(B细胞和T细胞)。用CHA处理荷肿瘤大鼠导致滤泡生发中心大小显著减小。滤泡套层、边缘区和红髓中的B淋巴细胞数量显著减少。边缘区和红髓中的CD8 + T细胞数量也减少,而动脉周围淋巴鞘(PALS)和红髓中的CD4 + T细胞数量增加。脾脏对sTAA疫苗接种的反应表现为白髓大部分区域大小显著增加以及B淋巴细胞数量增加。在对照大鼠或用CHA处理的大鼠的淋巴结中,CD8 +淋巴细胞主要聚集在皮质旁区。在用sTAA处理的大鼠中,CD8 +淋巴细胞也聚集在髓质。这些大鼠中CD4 + T细胞数量急剧增加,主要聚集在血管周围的髓质中。肿瘤不同区域(外周与深部)的淋巴细胞总数变化不同。肿瘤深部的CD8 +细胞数量显著增加,并且肿瘤深部这些细胞数量与外周相比的比例也增加。未发现淋巴细胞对不同类型处理的反应有差异。所有研究结果表明,sTAA疫苗接种具有严格的抗肿瘤作用,可防止在发生强烈免疫反应时免疫系统出现功能不足。